GlassScriptPhysician profile
Howard Ira Brenner
NPI 1992708317
$19,111.79
in general payments reported to CMS, 2019-2025
43 companies · $2,171 in 2025
The $2,171 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,680 · 2020: $846 · 2021: $1,667 · 2022: $7,686 · 2023: $2,549 · 2024: $2,513 · 2025: $2,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,196 · Education: $36.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,195.97 |
| Education | $36.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $5,590.86 | 2022-2025 | Omvoh |
| Abbvie INC. | $5,386.31 | 2019-2025 | Rinvoq, Skyrizi, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,285.78 | 2019-2024 | Trulance, Xifaxan |
| Pfizer INC. | $986.48 | 2019-2025 | |
| Janssen Biotech, INC. | $779.71 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $676.64 | 2019-2024 | Entyvio |
| Gilead Sciences, INC. | $640.62 | 2019-2025 | |
| Celgene Corporation | $551.43 | 2021-2024 | Zeposia |
| Genzyme Corporation | $532.11 | 2022-2025 | |
| Ardelyx, INC. | $354.15 | 2022-2025 | Ibsrela |
| Boston Scientific Corporation | $232.35 | 2019-2024 | Compliance Endokit |
| Phathom Pharmaceuticals, INC. | $199.12 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $189.45 | 2024-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $174.69 | 2019-2024 | Dificid |
| Allergan, INC. | $166.92 | 2019-2020 |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$21,363.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Brenner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.